Clinical Trial

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of perioperative Cadonilimab combined with neoadjuvant chemotherapy versus neoadjuvant chemotherapy in patients with resectable ESCC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2025-12-24
Trial Details
NCT Number NCT07263919
Lead Sponsor Akeso
Conditions Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Enrollment 90 participants
Start Date 2025-12-19
Primary Completion 2030-03 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-31